Genomic Alterations in Langerhans Cell Histiocytosis
- PMID: 26461146
- DOI: 10.1016/j.hoc.2015.06.004
Genomic Alterations in Langerhans Cell Histiocytosis
Abstract
The discovery of recurrent somatic genomic alterations in Langerhans cell histiocytosis (LCH) has led to a new understanding of LCH as a clonal neoplastic disorder. Most of the abnormalities described to date affect the RAS/RAF/MEK/extracellular-signal-regulated kinase (ERK) pathway: more than 50% of LCH cases carry activating mutations in BRAF, whereas another 10% to 28% carry activating mutations of MAP2K1, which encodes MEK1. The pathogenetic importance of these mutations has been confirmed by reports of significant clinical responses to RAF inhibitors.
Keywords: BRAF; LCH; Langerhans cell histiocytosis; MAP2K1; MEK1.
Copyright © 2015 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous